Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So, my 2500 shs will become 416 shs, but at what price ?
If they have no confident and do r/s, they can lose confident from investors. They will have hard time funding their research if they play the same game in the future.
They didn't have to do a RS like they don't need to do a secondary offering soon, LOL. Question is will they do it before results are announced or after? Doing it before would telegraph that they don't have much confidence in the results, IMO.
Looking at the candlestick for the day, I think the company decided to do the RS EOD seeing it peaked and closed well off that intraday high and would head back down and they wanted to use the momentum for a better price post RS.
They might be selfish. They don't want investors to own tons of shares and make tons of profit if good news. Now investors make a few profit with good news. Bad news, I think it might go back to .60 cents. Unbelivable.
If z160 news is bad it would tank regardless. If news is good it will take off. There is no other news of substance in the near future.
They don't have to do r/s. They can make profit by selling stocks with good news! This might stop the momentum and this will tank.
It was set in motion weeks ago
Why they do r/s? It is already over $1. This stock was gaining momentum. This is crazy idea.
Glad I got out at 1.30 and went straight to the Bank to Deposit profit $$$$$$$$$$$$ HAHA!! Well timed Exit!!!
People fail to realize that this is a drug company. Profits can be huge and instantaneous. At a later profitable time this company will do a 2-1 or higher forward split. An R/S here is meaningless but only needed to be listed on Naz.
Money money money.
Re:read your post in a week, I think it may show that the blithering idiots have been through r/s's and its friggen "rare" that it benefits the shareholder, and if you think that this was done in a way which it bests helps the shareholders than we found the missing blithering idiot
From a future bagholder, I will buy again when its under $5, which should be no longer than about 2 weeks away.
Shares are trading at a 30% discount, what a buy. After hours volume is 1,069,587 shares bought, what a bargain.
I'm thinking about starting a biotech company. Raise a bunch of money and gets everyone's hope up over some bullshit drug that will never get approved. Then I'll dilute my stock and raise more money then do a reverse split but sell all my shares on the way up and then poof I'm gone with a buy out of my salary. Seems real difficult.
Wow! Ouch took that dry, Talk about manipulation, did expect a r/s, But not when it shoots to 1.30 and have huge news possibly in Oct,we got F****D, drive it up get a lot of New investors with the run, than R/s the next day, WTF!!!!
SURPRISED!!! Of course we are. The sp was over $1 to be in compliance, so why wouldn't be.
It's not so much the RS it's the bullshit timing and the insiders knowing before it happens and dumping all day after they run it up. A bunch of fucking crooks.
I am amazed that so many seem to be surprised that the RS actually happened.
That stock split is just terrible at end of day on top of that. Glad I got out early. Wall street are crooks remember that! And always take profit always!
GREAT Timing!! R/S just announced..
That should be illegal.
1 for 6 reverse split announced right at the end of the day. Typical. I guess the dump mid day was insiders. Fuc&ing crooks.
Zalicus Announces 1-for-6 Reverse Stock Split
Huuuuuge bids EOD Crazy Volume the Last 4days,Little Shake by MMS today,IMO something Big is up here
crazy ZLCS day!
PII : the results to come in october?
But very tight sl
I got kicked Out 1.24, in .854.... Back in 1.13
Out at 1.30 from .93 and .98 Entry! $$$ congrats!
Man glad i got out at 1.34! but buying back in to follow the bounce.
What in the world happened here? I sold earlier on today at 1.33 and was pissed it kept going up. Just checked back in and the bottom dropped out of this thing. Looks like I'm getting back in.
ZLCS Made Wall Street Journal Today!!!
http://online.wsj.com/article/PR-CO-20131002-905231.html
Yeah,Looks like she wants up IMO ;)
Glad I canceled my sell order @ 1.33 today. Gonna stay in for the ride and see where it goes.
ZLCS
Greater Fools Love Delcath, Zalicus On Orphan Drug Derpitude at TheStreet12:03pm EDT
Close above 1.35 Would be very powerfull imo
Just back from my Run,and she is Running again ;)
1.36x1.37 battle
Got free tickets
This is a month long play into earnings day! $$$$$$$$$ GLTA
This is awesome. Im not gonna complain!
Have no idea. Maybe someone knows they are getting govt funding. One of the orphan drug designation bennies.
What about the gap up at market opening?
Followers
|
75
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2191
|
Created
|
08/12/07
|
Type
|
Free
|
Moderators |
http://finance.yahoo.com/q/ks?s=ZLCS
http://www.form4oracle.com/company?cik=0001135906&ticker=crxx
Zalicus Inc., a biopharmaceutical company, engages in the development of drug candidates focusing on the treatment of pain and inflammation. The company's clinical and preclinical product candidates for pain, inflammation, and other central nervous system disorders include Synavive (CRx-102), a novel dissociated glucocorticoid product candidate, which has completed Phase II clinical trials in subjects with knee osteoarthritis, to treat immuno-inflammatory disorders; Prednisporin (FOV1101), a topical ophthalmic drug candidate containing low doses of the glucocorticoid prednisolone acetate and the immunosuppressant cyclosporine A; N-type and T-type calcium channel blockers for the treatment of chronic pain; and CRx-601, a formulation of carbidopa and levodopa for the treatment of Parkinson's disease. It is also developing CRx-401 for Type 2 diabetes; CRx-191 and CRx-197 for psoriasis. It has a research collaboration and license agreement with the Novartis Institutes of Biomedical Research; a collaboration agreement with PGxHealth, LLC for the development of ATL313, an adenosine A2A receptor agonist compound owned by PGxHealth; collaboration agreement with Mallinckrodt Inc., Fovea Pharmaceuticals SA, and National Institutes of Allergy and Infectious Diseases; and a cooperative research and development agreement with the United States Army Medical Research Institute for Infectious Diseases. The company was formerly known as CombinatoRx, Incorporated and changed its name to Zalicus Inc. on September 9, 2010. Zalicus Inc. was founded in 2000 and is based in Cambridge, Massachusetts.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |